Victory Capital Management Inc. Raises Stock Position in STAAR Surgical (NASDAQ:STAA)

Victory Capital Management Inc. increased its holdings in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 16.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 189,481 shares of the medical instruments supplier's stock after purchasing an additional 27,143 shares during the quarter. Victory Capital Management Inc. owned approximately 0.38% of STAAR Surgical worth $7,039,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Arcadia Investment Management Corp MI purchased a new position in STAAR Surgical during the 3rd quarter valued at about $37,000. Canada Pension Plan Investment Board acquired a new stake in shares of STAAR Surgical during the second quarter worth approximately $129,000. Van ECK Associates Corp raised its position in shares of STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock worth $129,000 after purchasing an additional 393 shares during the period. Larson Financial Group LLC bought a new position in STAAR Surgical in the 2nd quarter worth about $130,000. Finally, nVerses Capital LLC raised its position in shares of STAAR Surgical by 78.3% during the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier's stock worth $152,000 after buying an additional 1,800 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Stock Up 1.5 %

Shares of STAAR Surgical stock traded up $0.40 on Friday, reaching $27.03. The company's stock had a trading volume of 268,827 shares, compared to its average volume of 710,523. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of 60.52 and a beta of 0.61. STAAR Surgical has a 52 week low of $25.88 and a 52 week high of $52.68. The firm's fifty day simple moving average is $30.99 and its two-hundred day simple moving average is $36.81.

Wall Street Analysts Forecast Growth

STAA has been the topic of several recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $41.00 to $31.00 and set a "hold" rating on the stock in a report on Friday, November 1st. Finally, Stifel Nicolaus dropped their price target on STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a research note on Monday, August 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, STAAR Surgical currently has a consensus rating of "Hold" and an average target price of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.